You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • THU0099 Monitoring of abatacept in rheumatoid arthritis patients with previous failure to biotherapies suggests that CTLA-4/CD3E and/or CD28/CTLA-4 MRNA ratio may predict response to treatment at 3 months

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – other biologic treatment
THU0099 Monitoring of abatacept in rheumatoid arthritis patients with previous failure to biotherapies suggests that CTLA-4/CD3E and/or CD28/CTLA-4 MRNA ratio may predict response to treatment at 3 months

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Eljaafari A, Tartelin M, Aissaoui H, et al
THU0099 Monitoring of abatacept in rheumatoid arthritis patients with previous failure to biotherapies suggests that CTLA-4/CD3E and/or CD28/CTLA-4 MRNA ratio may predict response to treatment at 3 months
Annals of the Rheumatic Diseases 2013;71:187.